Celltrion Healthcare Co., Ltd.
091990
Rang in aandelen
#2142
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Aandeelprijs
$57.75
Laatst gesynchroniseerd: 2024-01-11
Marktkapitalisatie
$9.42B
Verandering (1 dag)
-0.25%
Verandering (1 jaar)
0.00%
Land
KR
Handel Celltrion Healthcare Co., Ltd. (091990)
Categorie
Healthcare
P/S-ratio voor Celltrion Healthcare Co., Ltd. (091990)
P/S-ratio op October 2026 TTM: 5.44
Volgens de meest recente financiële rapporten en aandelenkoers van Celltrion Healthcare Co., Ltd. is de huidige P/S-ratio (TTM) 5.44. Eind 2021 had het bedrijf een P/S-ratio van 7.25.
P/S-ratiohistoriek voor Celltrion Healthcare Co., Ltd. van 2014 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 5.44 | 16.07% |
| 2022 | 4.69 | -35.23% |
| 2021 | 7.25 | -17.28% |
| 2020 | 8.76 | -31.59% |
| 2019 | 12.81 | -35.25% |
| 2018 | 19.78 | 30.68% |
| 2017 | 15.14 | 12.59% |
| 2016 | 13.44 | -15.98% |
| 2015 | 16.00 | 9,049.06% |
| 2014 | 0.17 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.02 | 84.10% |
US
|
|
| 40.55 | 644.89% |
US
|
|
| 4.19 | -23.02% |
AU
|
|
| 10.44 | 91.83% |
NL
|
|
| 4.52 | -17.00% |
BE
|
